RecruitingNot ApplicableNCT05633303

Personalised Ablation Strategies in AF

Developing Dynamic Substrate Targeted Personalised Treatment Strategies in AF.


Sponsor

Barts & The London NHS Trust

Enrollment

160 participants

Start Date

Oct 14, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Atrial fibrillation (AF) is the most common arrhythmia with an expected rise in prevalence over the next decade. Catheter ablation is a safe treatment option in eliminating AF however, success rates still remains variable. Existing strategies do not take into account the differences in AF perpetuation mechanisms beyond the pulmonary veins (PVs) due to the underlying substrate. Here, I will investigate the differences in persistent AF mechanisms due to the underlying substrate and utilise these findings to generate AF mechanism specific ablation strategies. I have defined a new metric, rate-dependent conduction velocity (RDCV) slowing that has shown to correlate with sites of re-entry activity in AF. In this study, techniques and methods will be developed to measure RDCV slowing sites. The impact autonomic modulation has on AF mechanisms and CV dynamics will also be assessed. The hypothesis is that a combination of structural, electrical and autonomic remodelling play an important mechanistic role in persistent AF and ablation strategies adapted to target these will result in greater procedural success rate. The study findings have the potential to improve the success rate of catheter ablation in persistent AF thereby improve patient wellbeing and reduce the cost burden of AF treatment.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Patients undergoing catheter ablation for persistent AF (\<24 months AF duration and no previous left atrial ablation).
  • Able to provide informed consent

Exclusion Criteria3

  • Unwillingness to sign consent
  • Age \<18 years
  • Contraindications for catheter ablation procedure

Interventions

OTHERSubstrate guided ablation

Ablation strategy implemented will be dependent on the Arm the patient has been allocated to based on the presence of underlying LVZs.


Locations(1)

Barts Heart Centre, Barts Health NHS trust

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05633303


Related Trials